Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders

Current Opinion in Neurobiology

Volumn 7, Issue 5, 1997, Pages 674-682

  Léna, Clément ^a   Changeux, Jean Pierre ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; ION CHANNEL; MEMBRANE PROTEIN; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; BRAIN DISEASE; CLINICAL TRIAL; DOPAMINE RELEASE; DRUG ABUSE; FRONTAL LOBE EPILEPSY; GENE MUTATION; GILLES DE LA TOURETTE SYNDROME; HUMAN; MEMORY; MENTAL DISEASE; MYASTHENIA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0343131930     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-4388(97)80088-8     Document Type: Article

References (75)

1. Changeux JP: The acetylcholine receptor: an "allosteric" membrane protein. Harvey Lectures 1980, 75:85-254.
2. Galzi JL, Changeux JP: Neuronal nicotinic receptors: molecular organization and regulations. Neuropharmacology 1995, 34:563-582.
3. Role LW, Berg DK: Nicotinic receptors in the development and modulation of CNS synapses. Neuron 1996, 16:1077-1085.
4. Tsigelny I, Sugiyama N, Sine SM, Taylor P: A model of the nicotinic receptor extracellular domain based on sequence identity and residue location. Biophys J 1997, 73:52-66.
5. McGehee DS, Role LW: Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995, 57:521-546.
6. Gerzanich V, Kuryatov A, Anand R, Lindstrom J: Orphan alpha 6 nicotinic AChR subunit can form a functional heteromeric acetylcholine receptor. Mol Pharmacol 1997, 51:320-327. This paper provides the first indication that the α6 nicotinic subunit may contribute to a functional nicotinic receptor. This result is potentially relevant to the topic of nicotine addiction because the mesencephalic dopaminergic neurons express high amounts of the α6 subunit [9•].
7. Ramirez Latorre J, Yu CR, Qu X, Perin F, Karlin A, Role L: Functional contributions of alpha 5 subunit to neuronal acetylcholine receptor channels. Nature 1996, 380:347-351.
8. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, Lindstrom J: Assembly of human neuronal nicotinic receptor alpha 5 subunits with alpha 3, beta 2, and beta 4 subunits. J Biol Chem 1996, 271:17656-17665. This work documents the differences in pharmacological properties of human nAChRs when they contain two or three different subunits.
9. Le Novère N, Zoli M, Changeux JP: Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci 1996, 8:2428-2439. In situ hybridization of the α6 and β3 subunits in rat brain demonstrated that these subunits are expressed at high levels in catecholaminergic neurons. Semi-quantitative analysis showed that the mRNA coding for these subunits are actually more abundant than the mRNA coding for all other subunits expressed in the structure. These results suggest that α6β3β2-containing nAChRs contribute to the nicotinic responses of dopaminergic neurons.
10. Changeux JP: Functional architecture and dynamics of the nicotinic acetylcholine receptor: an allosteric ligand-gated ion channel. In Fidia Research Foundation Neuroscience Award Lectures. Edited by Llinas RR, Changeux JP, Purves L, Bloom FE. New York: Raven Press Ltd; 1990:21-168.
11. Edelstein SJ, Schaad O, Henry E, Bertrand D, Changeux JP: A kinetic mechanism for nicotinic acetylcholine receptors based on multiple allosteric transitions. Biol Cybern 1996, 75:361-379. This paper applies the four-state allosteric model to the kinetics and single-channel stochastic properties of nAChRs. By proposing a systematic method for determining the parameters, the authors offer an accurate alternative to the classical sequential model.
12. Peng X, Katz M, Gerzanich V, Anand R, Lindstrom J: Human alpha7 acetylcholine receptor: cloning of the alpha7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha7 homomers expressed in Xenopus oocytes. Mol Pharmacol 1994, 45:546-554.
13. Gerzanich V, Peng X, Wang F, Wells G, Anand R, Fletcher S, Lindstrom J: Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol 1995, 48:774-782.
14. Gopalakrishnan M, Buisson B, Touma E, Giordano T, Campbell JE, Hu IC, Donnelly RD, Arneric SP, Bertrand D, Sullivan JP: Stable expression and pharmacological properties of the human alpha7 nicotinic acetylcholine receptor. Eur J Pharmacol 1995, 290:237-246.
15. Buisson B, Gopalakrishnan M, Arneric SP, Sullivan JP, Bertrand D: Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. J Neurosci 1996, 16:7880-7891.
16. Chavez Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC: Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h-alpha2beta2, h-alpha2beta4, h-alpha3beta2, h-alpha3beta4, h-alpha4beta2, h-alpha4beta4 and h-alpha7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 1997, 280:346-356. This comprehensive paper provides a pharmacological characterization of the human nAChRs containing one or two different subunits in Xenopus oocytes. The authors report significant differences between rodent and human nicotinic pharmacology.
17. Edelstein SJ, Changeux JP: Allosteric proteins after thirty years: the binding and state functions of the neuronal alpha7 nicotinic acetylcholine receptors. Experientia 1996, 52:1083-1090.
18. Revah F, Bertrand D, Galzi JL, Devillers-Thiery A, Mulle C, Hussy N, Bertrand S, Ballivet M, Changeux JP: Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature 1991, 353:846-849.
19. Galzi JL, Bertrand D, Devillers-Thiery A, Revah F, Bertrand S, Changeux JP: Functional significance of aromatic amino acids from three peptide loops of the alpha7 neuronal nicotinic receptor site investigated by site-directed mutagenesis. FEBS Lett 1991, 294:198-202.
20. Devillers-Thiery A, Galzi JL, Bertrand S, Changeux JP, Bertrand D: Stratified organization of the nicotinic acetylcholine receptor channel. Neuroreport 1992, 3:1001-1004.
21. Bertrand D, Devillers-Thiery A, Revah F, Galzi JL, Hussy N, Mulle C, Bertrand S, Ballivet M, Changeux JP: Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain. Proc Natl Acad Sci USA 1992, 89:1261-1265.
22. Labarca C, Nowak MW, Zhang H, Tang L, Deshpande P, Lester HA: Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors. Nature 1995, 376:514-516.
23. Galzi JL, Edelstein SJ, Changeux J: The multiple phenotypes of allosteric receptor mutants. Proc Natl Acad Sci USA 1996, 93:1853-1858. This paper provides a framework based on the allosteric model for the interpretation of the diverse phenotypes of point-mutated nAChRs, in particular of α7 nAChRs mutated in the channel domain.
24. Zoli M, Le Novere N, Hill JJ, Changeux JP: Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J Neurosci 1995, 15:1912-1939.
25. Changeux JP, Bessis A, Bourgeois JP, Corringer PJ, Devillers-Thiery A, Eisele JL, Kerszberg M, Lena C, Le Novere N, Picciotto M, Zoli M: Nicotinic receptors and brain plasticity. Cold Spring Harb Symp Quant Biol 1996, 61:343-362.
26. Treinin M, Chalfie M: A mutated acetylcholine receptor subunit causes neuronal degeneration in C. elegans. Neuron 1995, 14:871-877.
27. Ohno K, Wang HL, Milone M, Bren N, Brengman JM, Nakano S, Quiram P, Pruitt JN, Sine SM, Engel AG: Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit. Neuron 1996, 17:157-170.
28. Ohno K, Quiram PA, Milone M, Wang HL, Harper MC, Pruitt JN, Brengman JM, Pao L, Fischbeck KH, Crawford TO et al.: Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene - identification and functional characterization of six new mutations. Hum Mol Genet 1997, 6:753-766.
29. Engel AG, Ohno K, Bouzat C, Sine SM, Griggs RC: End-plate acetylcholine receptor deficiency due to nonsense mutations in the epsilon subunit. Ann Neurol 1996, 40:810-817.
30. Witzemann V, Schwarz H, Koenen M, Berberich C, Villarroel A, Wernig A, Brenner HR, Sakmann B: Acetylcholine receptor epsilon-subunit deletion causes muscle weakness and atrophy in juvenile and adult mice. Proc Natl Acad Sci USA 1996, 93:13286-13291.
31. Ohno K, Hutchinson DO, Milone M, Brengman JM, Bouzat C, Sine SM, Engel AG: Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit. Proc Natl Acad Sci USA 1995, 92:758-762.
32. Sine SM, Ohno K, Bouzat C, Auerbach A, Milone M, Pruitt JN, Engel AG: Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 1995, 15:229-239.
33. Engel AG, Ohno K, Milone M, Wang HL, Nakano S, Bouzat C, Pruitt J, Hutchinson DO, Brengman JM, Bren N, Sieb JP, Sine SM: New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol-Genet 1996, 5:1217-1227.
34. Gomez CM, Maselli R, Gammack J, Lasalde J, Tamamizu S, Cornblath DR, Lehar M, McNamee M, Kuncl RW: A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome. Ann Neurol 1996, 39:712-723.
35. Croxen R, Newland C, Beeson D, Oosterhuis H, Chauplannaz G, Vincent A, Newsom-Davis J: Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1997, 6:767-774.
36. Milone M, Wang H, Ohno K, Fukudome T, Pruitt J, Bren N, Sine S, Engel A: Slow-channel myasthenic syndrome caused by enhanced activation, desensitization and agonist binding affinity attributable to mutation in the M2 domain of acetylcholine receptor alpha subunit. J Neurosci 1997, 17:5651-5665.
37. Gomez CM, Maselli R, Gundeck JE, Chao M, Day JW, Tamamizu S, Lasalde JA, McNamee M, Wollmann RL: Slow-channel transgenic mice - a model of postsynaptic organellar degeneration at the neuromuscular junction. J Neurosci 1997, 17:4170-4179. This key work studies the effect of a mutation in the channel domain of the nAChR ε subunit previously identified by the authors as being responsible for a human congenital myasthenic syndrome. The transgenic mice exhibit a wide spectrum of neurophysiological and histological defects highly reminiscent of, if not identical to, the defects observed in humans. This provides a clear demonstration of the cytotoxicity of a mutation increasing the open-channel duration of muscle nAChRs.
38. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF: A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995, 11:201-203.
39. Weiland S, Witzemann V, Villarroel A, Propping P, Steinlein O: An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. FEBS Lett 1996, 398:91-96. This paper examines the consequence of the α4S248F mutation responsible for a human idiopathic epileptic disease [38]. In oocyte experiments, the mutated nAChRs exhibit an increased rate of desensitization and apparent affinity for acetytcholine.
40. Steinlein OK, Magnusson A, Stoodt J, Bertrand S, Weiland S, Berkovic SF, Nakken KO, Propping P, Bertrand D: An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Hum Mol Genet 1997, 6:943-947. This paper describes a novel mutation in the α4 nicotinic subunit gene associated with familial nocturnal frontal lobe epilepsies. This mutation results from the insertion of a leucine in the transmembrane domain lining the ion channel. The effect of this mutation on the function of the receptor is examined in oocyte experiments.
41. Bertrand D, Galzi JL, Devillers-Thiery A, Bertrand S, Changeux JP: Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha7 nicotinic receptor. Proc Natl Acad Sci USA 1993, 90:6971-6975.
42. Lynch JW, Rajendra S, Pierce KD, Handford CA, Barry PH, Schofield PR: Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel. EMBO J 1997, 16:110-120.
43. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, Le Novère N, Vincent P, Merlo Pich E, Brûlet P, Changeux JP: Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995, 374:65-67.
44. 2+ ions in nicotinic facilitation of GABA release in mouse thalamus. J Neurosci 1997, 17:576-585. This paper shows that β2-containing nAChRs increase the spontaneous and evoked release of GABA in the mouse thalamus. This effect is attributable to an influx of calcium in the nerve terminal. Different pathways of calcium influx are recruited, depending on the type of nerve terminal.
45. Orr Urtreger A, Noebels JL, Goldner FM, Patrick J, Beaudet AL: A novel hypersynchronous neocortical EEG phenotype in mice deficient in the neuronal nicotinic acetylcholine receptor (nAChRs) alpha7 subunit gene. Am J Hum Genet 1996, 59:A53.
46. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL: Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995, 64:749-760.
47. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, Brown A, Perry RH: Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995, 64:385-395.
48. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL: Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 1988, 95:171-175.
49. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA: Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 1992, 108:485-494.
50. Marchi M, Raiteri M: Nicotinic autoreceptors mediating enhancement of acetylcholine release become operative in conditions of 'impaired' cholinergic presynaptic function. J Neurochem 1996, 67:1974-1981. This paper confirms that nicotine increases the release of acetylcholine in slices and synaptosomes of rat cortex. It further shows indications that nAChRs on cholinergic terminals preferentially increase the release of acetylcholine under conditions of 'impaired' acetylcholine release.
51. Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly RD, Radek RJ, Marsh KC, Kyncl J et al.: Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties. Alzheimer Dis Assoc Disord 1995, 9(suppl2):50-61.
52. Cosford ND, Bleicher L, Herbaut A, McCallum JS, Vernier JM, Dawson H, Whitten JP, Adams P, Chavez NL, Correa LD et al.: (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 1996, 39:3235-3237.
53. Lippiello PM, Bencherif M, Gray JA, Peters S, Grigoryan G, Hodges H, Collins AC: RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization. J Pharmacol Exp Ther 1996, 279:1422-1429.
54. Dehaene S, Changeux JP: The Wisconsin card sorting test: theoretical analysis and modeling in a neuronal network. Cereb Cortex 1991, 1:62-79.
55. Pennartz C: The ascending neuromodulatory systems in learning by reinforcement-comparing computational conjectures with experimental findings. Brain Res Rev 1996, 21:219-245.
56. Altman J, Everitt BJ, Glautier S, Markou A, Nutt D, Oretti R, Phillips GD, Robbins TW: The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacology 1996, 125:285-345. A well-documented critical review of data and interpretations regarding drug addiction.
57. Rose JE, Corrigall WA: Nicotine self-administration in animals and humans - similarities and differences. Psychopharmacology 1997, 130:28-40.
58. Pontieri FE, Tanda G, Orzi F, Di Chiara G: Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382:255-257. 2-deoxyglucose autoradiography and brain microdialysis demonstrate a specific increase of metabolism and release of dopamine in the shell of the nucleus accumbens following injection of minimal doses of nicotine. Similar effects have also been described for cocaine, amphetamine and morphine, and are likely to be associated with the addictive properties of these drugs. These results, though not acquired in the context of nicotine self-administration, are thus strongly in favour of an addictive action of nicotine.
59. Merlo Pich E, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C: Common neural substrates for the addictive properties of nicotine and cocaine. Science 1997, 275:83-86. Regional brain activation following nicotine and cocaine self-administration is assessed by mapping Fos-like immunoreactivity. Similar patterns of activation are observed for both drugs in the terminal fields of the mesocorticolimbic system, supporting the view that self-administration of nicotine is associated with an activation of the mesencephalic dopaminergic system, as observed for other reinforcing drugs.
60. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP et al.: Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996, 379:733-736.
61. Henningfield JE, Miyasato K, Jasinski DR: Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav 1983, 19:887-890.
62. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio L, Merlo Pich E, Fuxe K, Changeux JP: β-2-containing acetylcholine receptors are involved in the reinforcing properties of nicotine. Nature 1997, in press.
63. Nisell M, Nomikos GG, Svensson TH: Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 1995, 76:157-162.
64. Levin ED, Wilson W, Rose JE, McEvoy J: Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996, 15:429-436.
65. Shytle RD, Silver AA, Philipp MK, Mcconville BJ, Sanberg PR: Transdermal nicotine for Tourette's syndrome. Drug Dev Res 1996, 38:290-298. Transdermal nicotine substantially alleviates the symptoms of Tourette's syndrome. Nicotine therefore appears as a promising adjunct to neuroleptic therapies of this disease.
66. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J: Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 1996, 123:55-63. This paper provides initial indications of a possible use of nicotine in the treatment of attention-deficit/hyperactivity disorder.
67. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F: Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 1994, 116:117-119.
68. Clemens P, Baron JA, Coffey D, Reeves A: The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology 1995, 117:253-256.
69. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, Coon H, Griffith JM, Miller C, Myles WM et al.: Nicotinic receptor function in schizophrenia. Schizophr Bull 1996, 22:431-445.
70. Freedman R, Hall M, Adler LE, Leonard S: Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995, 18:537-551.
71. Freedman R, Coon H, Mylesworsley M, Orr Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M et al.: Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997, 94:587-592. An inheritable symptomatic deficit in sensory gating, frequently observed in schizophrenics, is linked with a genetic marker neighbouring the locus of the α7 nicotinic receptor gene, raising the possibility of a change in nicotinic receptor function in some forms of schizophrenia.
72. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW: Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995, 269:1692-1696.
73. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA: Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996, 383:713-716. Low doses of nicotine, comparable to a smoker's plasma concentration of nicotine, activate presynaptic α-bungarotoxin-sensitive nAChRs on the glutamatergic nerve terminals in hippocampal neurons. This is the first (in vitro) indication in mammals that α-bungarotoxin-sensitive nAChRs might be activated under the conditions of tobacco smoking.
74. Lefkowitz RJ, Cotecchia S, Samama P, Costa T: Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 1993, 14:303-307.
75. Gomez CM, Gammack JT: A leucine-to-phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow-channel syndrome. Neurology 1995, 45:982-985.